Mankind Pharma is in talks with PE companies to acquire Bharat Serums and Vaccines. Owner Advent International aims to sell BSV for over $2 billion, with the final transaction expected to be ...

Mankind Pharma has announced a definitive agreement for the acquisition of a 100% stake in Bharat Serums and Vaccines (BSV) from private equity investor Advent International in a Rs136.3bn ($1.6bn ...

As Mankind Pharma gears up to go public, its 544-page draft IPO paper throws up an interesting name, Dabur India. One wonders why would a century-old fast-moving consumer goods (FMCG) major be ...

Mankind Pharma Limited on Wednesday announced that it has completed the transaction to acquire 100% stake in Bharat Serums and Vaccines Limited (BSV), for a purchase consideration of Rs.

Brothers Ramesh (left) and Rajeev Juneja at Mankind Pharma's headquarters in Delhi. Mankind Pharma—owned by Indian billionaire brothers Ramesh and Rajeev Juneja— has agreed to buy Bharat ...

Mankind had a 4.4% share of the highly fragmented domestic pharma market as of end-August. Analyst Shah says moving into the top three “is not an impossible goal.” But Mankind faces challenges.

As I step into Rajeev Juneja’s office at Mankind Pharma’s Delhi headquarters, the wall in front of me immediately commands attention. It features a collection of iconic quotes and striking ...

Mankind Pharma Ltd said it had entered into a definitive agreement to acquire a 100% stake in Bharat Serums and Vaccines Ltd (BSV) from private equity firm Advent International for an enterprise ...

Mankind Pharma, a pharma/ consumer healthcare (HC) player ranked fourth by sales in the IPM (Indian Pharmaceutical Market), is IPO-bound (April 25-27). The offer is entirely an OFS of ₹4,326 ...